Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose oral and subcutaneous NNC0519-0130 pharmacokinetics in Japanese and non-Japanese males
jRCT2071230015Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0519-0130 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period, Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period and 1 more. Started May 2023; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2071230015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230015.